Insider Buying: INmune Bio Inc (INMB) CFO Purchases 5,000 Shares of Stock

INmune Bio Inc (NASDAQ:INMB) CFO David J. Moss purchased 5,000 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was acquired at an average cost of $9.00 per share, with a total value of $45,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of NASDAQ:INMB traded down $0.08 during trading on Thursday, reaching $10.40. The company had a trading volume of 4,300 shares, compared to its average volume of 17,216. INmune Bio Inc has a twelve month low of $7.00 and a twelve month high of $11.50.

Separately, Maxim Group set a $13.00 price target on shares of INmune Bio and gave the stock a “buy” rating in a research note on Thursday, May 16th.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Rockland Register and is owned by of Rockland Register. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://rocklandregister.com/2019/05/30/inmune-bio-inc-inmb-cfo-david-j-moss-acquires-5000-shares-of-stock.html.

INmune Bio Company Profile

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Featured Article: How do CD ladders protect against rising interest rates?

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.